Recon: Merck Acquires Immune Design for $300M; CMS Projects US Health Spending to Rise 5.5% Annually Over the Next Decade - Regulatory Focus

Recon: Merck Acquires Immune Design for $300M; CMS Projects US Health Spending to Rise 5.5% Annually Over the Next Decade  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. US health spending to rise 5.5 percent per year ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more